Circadian and sleep disorder in Huntington's disease

Experimental Neurology

Volumn 243, Issue , 2013, Pages 34-44

  Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

A good night's sleep; Accelerated aging; Alzheimer's disease; Cognitive function; Daytime sleepiness; Memory; Neurodegeneration; Parkinson's disease; R6 2 mice; Sleep; Somnolence

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; CLONAZEPAM; DIAZEPAM; DOSULEPIN; MELATONIN; MODAFINIL; OLANZAPINE; QUETIAPINE; RILUZOLE; TETRABENAZINE; VENLAFAXINE; ZOPICLONE;

BASAL GANGLION; BRAIN CORTEX; BRAIN STEM; CIRCADIAN RHYTHM; CLINICAL FEATURE; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DISEASE MODEL; DROWSINESS; ELECTROENCEPHALOGRAPHY; HUMAN; HUNTINGTON CHOREA; HYPNOSIS; HYPOTHALAMUS; INSOMNIA; LIVER METABOLISM; MOOD DISORDER; NONHUMAN; NONREM SLEEP; PERIPHERAL CLOCK; PRIORITY JOURNAL; REM SLEEP; REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP FRAGMENTATION; SLEEP SPINDLE; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

ANIMALS; CIRCADIAN RHYTHM; HUMANS; HUNTINGTON DISEASE; SLEEP DISORDERS; SLEEP STAGES;

EID: 84875381701     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.014     Document Type: Review

References (141)

1. Aarsland D., Alves G., Larsen J.P. Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. Adv. Neurol. 2005, 96:56-64.
2. Adler C.H., Caviness J.N., Hentz J.G., Lind M., Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov. Disord. 2003, 18:287-293.
3. Albrecht U. Timing to perfection: the biology of central and peripheral circadian clocks. Neuron 2012, 74:246-260.
4. André V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci. Ther. 2010, 16:163-178.
5. Andrich J., Schmitz T., Saft C., Postert T., Kraus P., Epplen J.T., Przuntek H., Agelink M.W. Autonomic nervous system function in Huntington's disease. J. Neurol. Neurosurg. Psychiatry 2002, 72:726-731.
6. Arnulf I., Nielsen J., Lohmann E., Schiefer J., Wild E., Jennum P., Konofal E., Walker M., Oudiette D., Tabrizi S., Durr A. Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 2008, 65:482-488.
7. Aron A.R., Schlaghecken F., Fletcher P.C., Bullmore E.T., Eimer M., Barker R., Sahakian B.J., Robbins T.W. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease. Brain 2003, 126:713-723.
8. Asher G., Schibler U. Crosstalk between components of circadian and metabolic cycles in mammals. Cell Metab. 2011, 2:125-137.
9. Askenasy J.J. Approaching disturbed sleep in late Parkinson's disease: first step toward a proposal for a revised UPDRS. Parkinsonism Relat. Disord. 2001, 8:123-131.
10. Aziz N.A., Swaab D.F., Pijl H., Roos R.A. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev. Neurosci. 2007, 18:223-251.
11. Aziz N.A., Pijl H., Frölich M., Schröder-van der Elst J.P., van der Bent C., Roelfsema F., Roos R.A. Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J. Neurol. 2009, 256:1961-1965.
12. Aziz N.A., Pijl H., Frölich M., van der Graaf A.W., Roelfsema F., Roos R.A. Increased hypothalamic-pituitary-adrenal axis activity in Huntington's disease. J. Clin. Endocrinol. Metab. 2009, 94:1223-1228.
13. Aziz N.A., Anguelova G.V., Marinus J., Lammers G.J., Roos R.A. Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat. Disord. 2010, 16:345-350.
14. Barbanoj M.J., Clos S., Romero S., Morte A., Giménez S., Lorenzo J.L., Luque A., Dal-Ré R. Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. Neuropsychobiology 2005, 51:134-147.
15. Bates G.P., Harper P.S., Jones L. Eds. Huntington's disease 2002, Oxford UP, Oxford. third ed.
16. Bechtold D.A., Gibbs J.E., Loudon A.S. Circadian dysfunction in disease. Trends Pharmacol. Sci. 2010, 31:191-198.
17. Bianchetti A., Scuratti A., Zanetti O., Binetti G., Frisoni G.B., Magni E., Trabucchi M. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia 1995, 6:108-112.
18. Blackwell A.D., Paterson N.S., Barker R.A., Robbins T.W., Sahakian B.J. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology 2008, 199:29-36.
19. Bode F.J., Stephan M., Wiehager S., Nguyen H.P., Björkqvist M., von Hörsten S., Bauer A., Petersén A. Increased numbers of motor activity peaks during light cycle are associated with reductions in adrenergic alpha(2)-receptor levels in a transgenic Huntington's disease rat model. Behav. Brain Res. 2009, 14:175-182.
20. Bollen E.L., Den Heijer J.C., Ponsioen C., Kramer C., Van der Velde E.A., Van Dijk J.G., Roos R.A., Kamphuisen H.A., Buruma O.J. Respiration during sleep in Huntington's chorea. J. Neurol. Sci. 1988, 84:63-68.
21. Bombois S., Derambure P., Pasquier F., Monaca C. Sleep disorders in aging and dementia. J. Nutr. Health Aging 2010, 14:212-217.
22. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence- based review. Curr. Pharm. Des. 2006, 12:2701-2720.
23. Bonuccelli U., Del Dotto P., Lucetti C., Petrozzi L., Bernardini S., Gambaccini G., Rossi G., Piccini Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin. Neuropharmacol. 2000, 23:28-33.
24. Cardinali D.P., Pagano E.S., Scacchi Bernasconi P.A., Reynoso R., Scacchi P. Melatonin and mitochondrial dysfunction in the central nervous system. Horm. Behav. 2012, 25. ([Epub ahead of print] PubMed PMID: 22391273).
25. Carter R.J., Hunt M.J., Morton A.J. Environmental stimulation increases survival in mice transgenic for exon 1 of the Huntington's disease gene. Mov. Disord. 2000, 15:925-937.
26. Challet E., Mendoza J., Dardente H., Pévet P. Neurogenetics of food anticipation. Eur. J. Neurosci. 2009, 30:1676-1687.
27. Cirelli C. The genetic and molecular regulation of sleep: from fruit flies to humans. Nat. Rev. Neurosci. 2009, 10:549-560.
28. Cuesta M., Aungier J., Morton A.J. The methamphetamine-sensitive circadian oscillator is dysfunctional in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2012, 45:145-155.
29. Cuturic M., Abramson R.K., Vallini D., Frank E.M., Shamsnia M. Sleep patterns in patients with Huntington's disease and their unaffected first-degree relatives: a brief report. Behav. Sleep Med. 2009, 7:245-254.
30. De Cruz S., Espiritu J.R., Zeidler M., Wang T.S. Sleep disorders in chronic liver disease. Semin. Respir. Crit. Care Med. 2012, 33:26-35.
31. Dibner C., Schibler U., Albrecht U. The mammalian circadian timing system:organization and coordination of central and peripheral clocks. Annu. Rev. Physiol. 2010, 72:517-549.
32. Dowling G.A., Mastick J., Colling E., Carter J.H., Singer C.M., Aminoff M.J. Melatonin for sleep disturbances in Parkinson's disease. Sleep Med. 2005, 6:459-466.
33. Dubocovich M.L. Melatonin receptors: role on sleep and circadian rhythm regulation. Sleep Med. 2007, 8:34-42.
34. Eismann E.A., Lush E., Sephton S.E. Circadian effects in cancer-relevantpsychoneuroendocrine and immune pathways. Psychoneuroendocrinology 2010, 35:963-976.
35. Ellenbogen J.M., Pace-Schott E.F. Drug-induced sleep: theoretical and practical considerations. Pflugers Arch. 2012, 463:177-186.
36. Emser W., Brenner M., Stober T., Schimrigk K. Changes in nocturnal sleep in Huntington's and Parkinson's disease. J. Neurol. 1988, 235:177-179.
37. España R.A., Scammell T.E. Sleep neurobiology from a clinical perspective. Sleep 2011, 1:845-858.
38. Faraguna U., Vyazovskiy V.V., Nelson A.B., Tononi G., Cirelli C. A causal role for brain-derived neurotrophic factor in the homeostatic regulation of sleep. J. Neurosci. 2008, 9:4088-4095.
39. Fava M. Daytime sleepiness and insomnia as correlates of depression. J. Clin. Psychiatry 2004, 65:27-32.
40. Feillet C.A., Mendoza J., Pévet P., Challet E. Restricted feeding restores rhythmicity in the pineal gland of arrhythmic suprachiasmatic-lesioned rats. Eur. J. Neurosci. 2008, 28:2451-2458.
41. Fish D.R., Sawyers D., Allen P.J., Blackie J.D., Lees A.J., Marsden C.D. The effect of sleep on the dyskinetic movements of Parkinson's disease, Gilles de la Tourette syndrome, Huntington's disease, and torsion dystonia. Arch. Neurol. 1991, 48:210-214.
42. Foster R.G., Wulff K. The rhythm of rest and excess. Nat. Rev. Neurosci. 2005, 6:407-414.
43. Gaig C., Iranzo A. Sleep-disordered breathing in neurodegenerative diseases. Curr. Neurol. Neurosci. Rep. 2012, 12:205-217.
44. García-Martínez R., Córdoba J. Acute-on-chronic liver failure: the brain. Curr. Opin. Crit. Care 2011, 17:177-183.
45. Garfinkel D., Laudon M., Zisapel N. Improvement of sleep quality by controlled-release melatonin in benzodiazepine-treated elderly insomniacs. Arch. Gerontol. Geriatr. 1997, 24:223-231.
46. Gaus S.E., Lin L., Mignot E. CSF hypocretin levels are normal in Huntington's disease patients. Sleep 2005, 28:1607-1608.
47. Ghilardi M.F., Silvestri G., Feigin A., Mattis P., Zgaljardic D., Moisello C., Crupi D., Marinelli L., Dirocco A., Eidelberg D. Implicit and explicit aspects of sequence learning in pre-symptomatic Huntington's disease. Parkinsonism Relat. Disord. 2008, 14:457-464.
48. Ghosh P.S., Hupertz V., Ghosh D. Neurological complications following pediatric liver transplant. J. Pediatr. Gastroenterol. Nutr. 2012, 54:540-546.
49. Gonzales E., Yin J. Drosophila models of Huntington's disease exhibit sleep abnormalities. PLoS Curr. 2010, 29:2.
50. Goodman A.O., Barker R.A. How vital is sleep in Huntington's disease?. J. Neurol. 2010, 257:882-897.
51. Goodman A.O., Morton A.J., Barker R.A. Identifying sleep disturbances in Huntington's disease using a simple disease-focused questionnaire. PLoS Curr. 2010, 15:2.
52. Goodman A.O., Rogers L., Pilsworth S., McAllister C.J., Shneerson J.M., Morton A.J., Barker R.A. Asymptomatic sleep abnormalities are a common early feature in patients with Huntington's disease. Curr. Neurol. Neurosci. Rep. 2011, 11:211-217.
53. Green C.B., Takahashi J.S., Bass J. The meter of metabolism. Cell 2008, 134:728-742.
54. Hansotia P., Wall R., Berendes J. Sleep disturbances and severity of Huntington's disease. Neurology 1985, 35:1672-1674.
55. Hatfield C.F., Herbert J., van Someren E.J., Hodges J.R., Hastings M.H. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 2004, 127:1061-1074.
56. Hauw J.J., Hausser-Hauw C., De Girolami U., Hasboun D., Seilhean D. Neuropathology of sleep disorders: a review. J. Neuropathol. Exp. Neurol. 2011, 70:243-252.
57. Hindmarch I., Dawson J., Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005, 28:187-193.
58. Hobbs N.Z., Henley S.M., Ridgway G.R., Wild E.J., Barker R.A., Scahill R.I., Barnes J., Fox N.C., Tabrizi S.J. The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J. Neurol. Neurosurg. Psychiatry 2010, 81:756-763.
59. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann. Neurol. 2002, 51:235-242.
60. Högl B., Saletu M., Brandauer E., Glatzl S., Frauscher B., Seppi K., Ulmer H., Wenning G., Poewe W. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002, 25:905-909.
61. Honma K., Honma S. The SCN-independent clocks, methamphetamine and food restriction. Eur. J. Neurosci. 2009, 30:1707-1717.
62. Honma K., Honma S., Hiroshige T. Disorganization of the rat activity rhythm bychronic treatment with methamphetamine. Physiol. Behav. 1986, 38:687-695.
63. Honma K., Honma S., Hiroshige T. Activity rhythms in the circadian domain appear in suprachiasmatic nuclei lesioned rats given methamphetamine. Physiol. Behav. 1987, 40:767-774.
64. Hult S., Schultz K., Soylu R., Petersén A. Hypothalamic and neuroendocrine changes in Huntington's disease. Curr. Drug Targets 2010, 11:1237-1249.
65. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 26:971-983. Huntington's Disease Collaborative Research Group.
66. Iakhno N.N. Disorders of nocturnal sleep in Huntington chorea. Zh. Nevropatol. Psikhiatr. Im. S. S. Korsakova 1985, 85:340-346.
67. Jewett M.E., Kronauer R.E. Interactive mathematical models of subjective alertness and cognitive throughput in humans. J. Biol. Rhythms 1999, 14:588-597.
68. Kassubek J., Juengling F.D., Ecker D., Landwehrmeyer G.B. Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb. Cortex 2005, 15:846-853.
69. Kobal J., Melik Z., Cankar K., Bajrovic F.F., Meglic B., Peterlin B., Zaletel M. Autonomic dysfunction in presymptomatic and early symptomatic Huntington's disease. Acta Neurol. Scand. 2010, 121:392-399.
70. Kubitz K.A., Landers D.M., Petruzzello S.J., Han M. The effects of acute and chronic exercise on sleep. A meta-analytic review. Sports Med. 1996, 21:277-291.
71. Kudo T., Schroeder A., Loh D.H., Kuljis D., Jordan M.C., Roos K.P., Colwell C.S. Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp. Neurol. 2011, 228:80-90.
72. Kushida C.A., Bergmann B.M., Rechtschaffen A. Sleep deprivation in the rat: IV. Paradoxical sleep deprivation. Sleep 1989, 12:22-30.
73. Kyriacou C.P., Hastings M.H. Circadian clocks: genes, sleep, and cognition. Trends Cogn. Sci. 2010, 14:259-267.
74. Leresche N., Lambert R.C., Errington A.C., Crunelli V. From sleep spindles of natural sleep to spike and wave discharges of typical absence seizures: is the hypothesis still valid?. Pflugers Arch. 2012, 463:201-212.
75. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum. Psychopharmacol. 2005, 20(8):533-559. (Dec).
76. Maywood E.S., O'Neill J., Wong G.K., Reddy A.B., Hastings M.H. Circadian timing in health and disease. Prog. Brain Res. 2006, 153:253-269.
77. Maywood E.S., Fraenkel E., McAllister C.J., Wood N.I., Reddy A.B., Hastings M.H., Morton A.J. Disruption of peripheral circadian timekeeping in a mouse model of Huntington's disease and its restoration by temporally scheduled feeding. J. Neurosci. 2010, 28:10199-10204.
78. Meier A., Mollenhauer B., Cohrs S., Rodenbeck A., Jordan W., Meller J., Otto M. Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Res. 2005, 30:201-203.
79. Mena-Segovia J., Cintra L., Prospero-Garca O., Giordano M. Changes in sleep-waking cycle after striatal excitotoxic lesions. Behav. Brain Res. 2002, 15:475-481.
80. Mistlberger R.E. Neurobiology of food anticipatory circadian rhythms. Physiol. Behav. 2011, 104:535-545.
81. Morris C.J., Aeschbach D., Scheer F.A. Circadian system, sleep and endocrinology. Mol. Cell. Endocrinol. 2012, 5:91-104.
82. Morton A.J., Wood N.I., Hastings M.H., Hurelbrink C., Barker R.A., Maywood E.S. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J. Neurosci. 2005, 5:157-163.
83. Oakeshott S., Balci F., Filippov I., Murphy C., Port R., Connor D., Paintdakhi A., Lesauter J., Menalled L., Ramboz S., Kwak S., Howland D., Silver R., Brunner D. Circadian abnormalities in motor activity in a BAC transgenic mouse model of Huntington's disease. PLoS Curr. 2011, 5:3.
84. O'Connor P.J., Youngstedt S.D. Influence of exercise on human sleep. Exerc. Sport Sci. Rev. 1995, 23:105-134.
85. Ohayon M.M., Carskadon M.A., Guilleminault C., Vitiello M.V. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004, 1:1255-1273.
86. Ondo W.G., Fayle R., Atassi F., Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry 2005, 76:1636-1639.
87. Pace-Schott E.F., Spencer R.M. Age-related changes in the cognitive function of sleep. Prog. Brain Res. 2011, 191:75-89.
88. Pace-Schott E.F., Navem G., Morgan A., Spencer R.M. Sleep-dependent modulation of affectively guided decision-making. J. Sleep Res. 2012, 21:30-39.
89. Pallier P.N., Morton A.J. Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease. Brain Res. 2009, 7:90-98.
90. Pallier P.N., Maywood E.S., Zheng Z., Chesham J.E., Inyushkin A.N., Dyball R., Hastings M.H., Morton A.J. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J. Neurosci. 2007, 18:7869-7878.
91. Pedroso J.L., Braga-Neto P., Felício A.C., Aquino C.C., Prado L.B., Prado G.F., Barsottini O.G. Sleep disorders in cerebellar ataxias. Arq. Neuropsiquiatr. 2011, 69:253-257.
92. Peigneux P., Laureys S., Fuchs S., Collette F., Perrin F., Reggers J., Phillips C., Degueldre C., Del Fiore G., Aerts J., Luxen A., Maquet P. Are spatial memories strengthened in the human hippocampus during slow wave sleep?. Neuron 2004, 28:535-545.
93. Petersén A., Björkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur. J. Neurosci. 2006, 24:961-967.
94. Petersén A., Gil J., Maat-Schieman M.L., Björkqvist M., Tanila H., Araújo I.M., Smith R., Popovic N., Wierup N., Norlén P., Li J.Y., Roos R.A., Sundler F., Mulder H., Brundin P. Orexin loss in Huntington's disease. Hum. Mol. Genet. 2005, 1:39-47.
95. Petit D., Gagnon J.F., Fantini M.L., Ferini-Strambi L., Montplaisir J. Sleep and quantitative EEG in neurodegenerative disorders. J. Psychosom. Res. 2004, 56:487-496.
96. Pevet P., Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J. Physiol. Paris 2011, 105:170-182.
97. Pezuk P., Mohawk J.A., Yoshikawa T., Sellix M.T., Menaker M. Circadian organization is governed by extra-SCN pacemakers. J. Biol. Rhythms 2010, 25:432-441.
98. Pidgeon C., Rickards H. The pathophysiology and pharmacological treatment of Huntington disease. Behav. Neurol. 2012, (Epub ahead of print).
99. Pietropaolo S., Delage P., Cayzac S., Crusio W.E., Cho Y.H. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice. PLoS One 2011, 6(5):e19965.
100. Plihal W., Born J. Effects of early and late nocturnal sleep on priming and spatial memory. Psychophysiology 1999, 36:571-582.
101. Politis M., Pavese N., Tai Y.F., Tabrizi S.J., Barker R.A., Piccini P. Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain 2008, 131:2860-2869.
102. Ransome M.I., Hannan A.J. Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6/1 Huntington's disease mice. Neurobiol. Learn. Mem. 2012, 97:261-270.
103. Rechtschaffen A., Bergmann B.M. Sleep deprivation in the rat: an update of the 1989 paper. Sleep 2002, 1:18-24.
104. Reddy A.B., Karp N.A., Maywood E.S., Sage E.A., Deery M., O'Neill J.S., Wong G.K., Chesham J., Odell M., Lilley K.S., Kyriacou C.P., Hastings M.H. Circadian orchestration of the hepatic proteome. Curr. Biol. 2006, 6:1107-1115.
105. Reppert S.M., Weaver D.R. Coordination of circadian timing in mammals. Nature 2002, 418:935-941.
106. Rongve A., Boeve B.F., Aarsland D. Frequency and correlates of caregiver-reported sleep disturbances in a sample of persons with early dementia. J. Am. Geriatr. Soc. 2010, 58:480-486.
107. Roos R.A., Aziz N.A. Hypocretin-1 and secondary signs in Huntington's disease. Parkinsonism Relat. Disord. 2007, 13:S387-S390.
108. Rudenko O., Tkach V., Berezin V., Bock E. Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage. Behav. Brain Res. 2009, 5:188-199.
109. Saper C.B., Fuller P.M., Pedersen N.P., Lu J., Scammell T.E. Sleep state switching. Neuron 2010, 22:1023-1042.
110. Schroeder A.M., Loh D.H., Jordan M.C., Roos K.P., Colwell C.S. Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease. PLoS Curr. 2011, 4:3:RRN1266.
111. Scott D.F., Heathfield K.W.B., Toone B., Margerison J.H. The EEG in Huntington's chorea: a clinical and neuropathological study. J. Neurol. Neurosurg. Psychiatry 1972, 335:97-102.
112. Sephton S., Spiegel D. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?. Brain Behav. Immun. 2003, 17:321-328.
113. Shan L., Hofman M.A., van Wamelen D.J., Van Someren E.J., Bao A.M., Swaab D.F. Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 2012, 1:713-715.
114. Sherrill D.L., Kotchou K., Quan S.F. Association of physical activity and human sleep disorders. Arch. Intern. Med. 1998, 158:1894-1898.
115. Shulman L.M., Taback R.L., Bean J., Weiner W.J. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov. Disord. 2001, 16:507-510.
116. Shulman L.M., Taback R.L., Rabinstein A.A., Weiner W.J. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 2002, 8:193-197.
117. Silvestri R., Raffaele M., De Domenico P., Tisano A., Mento G., Casella C., Tripoli M.C., Serra S., Di Perri R. Sleep features in Tourette's syndrome, neuroacanthocytosis and Huntington's chorea. Neurophysiol. Clin. 1995, 25:66-77.
118. Soneson C., Fontes M., Zhou Y., Denisov V., Paulsen J.S., Kirik D., Petersén A. Huntington Study Group PREDICT-HD investigators. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiol. Dis. 2010, 40:531-543.
119. Spiegel K., Tasali E., Penev P., Van Cauter E. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann. Intern. Med. 2004, 7:846-850.
120. Spiegel K., Leproult R., L'hermite-Balériaux M., Copinschi G., Penev P.D., VanCauter E. Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. J. Clin. Endocrinol. Metab. 2004, 89:5762-5771.
121. Takahashi I.J.S., Hong H.K., Ko C.H., McDearmon E.L. The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 2008, 9:764-775.
122. Tataroǧlu O., Davidson A.J., Benvenuto L.J., Menaker M. The methamphetamine-sensitive circadian oscillator (MASCO) in mice. J. Biol. Rhythms 2006, 21:185-194.
123. Thu D.C., Oorschot D.E., Tippett L.J., Nana A.L., Hogg V.M., Synek B.J., Luthi-Carter R., Waldvogel H.J., Faull R.L. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
124. Tietzel A.J., Lack L.C. The recuperative value of brief and ultra-brief naps on alertness and cognitive performance. J. Sleep. Res. 2002, 11:213-218.
125. Valentino R.M., Foldvary-Schaefer N. Modafinil in the treatment of excessive daytime sleepiness. Cleve. Clin. J. Med. 2007, 74:561-571.
126. Van Someren E.J.W. Circadian and sleep disturbances in the elderly. Exp. Gerontol. 2000, 35:1229-1237.
127. van Wamelen D.J., Shan L., Aziz N.A., Anink J.J., Bao A.M., Roos R.A., Swaab D.F. Functional increase of brain histaminergic signaling in Huntington's disease. Brain Pathol. 2011, 21:419-427.
128. Verwey M., Amir S. Food-entrainable circadian oscillators in the brain. Eur. J. Neurosci. 2009, 30:1650-1657.
129. Videnovic A., Leurgans S., Fan W., Jaglin J., Shannon K.M. Daytime somnolence and nocturnal sleep disturbances in Huntington disease. Parkinsonism Relat. Disord. 2009, 15:471-474.
130. Wiegand M., Möller A.A., Lauer C.J., Stolz S., Schreiber W., Dose M., Krieg J.C. Nocturnal sleep in Huntington's disease. J. Neurol. 1991, 238:203-208.
131. Wiegand M., Möller A.A., Schreiber W., Lauer C., Krieg J.C. Brain morphology and sleep EEG in patients with Huntington's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1991, 240:148-152.
132. Williams R.H., Morton A.J., Burdakov D. Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease. Neurobiol. Dis. 2011, 42:438-445.
133. Wood N.I., Carta V., Milde S., Skillings E.A., McAllister C.J., Ang Y.L., Duguid A., Wijesuriya N., Afzal S.M., Fernandes J.X., Leong T.W., Morton A.J. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease. PLoS One 2010, 12(5(2)):e9077.
134. Wood N.I., Glynn D., Morton A.J. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2011, 42:427-437.
135. Wood N.I., Sawiak S.J., Buonincontri G., Niu Y., Kane A.D., Carpenter T.A., Giussani D.A., Morton A.J. Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease. J. Huntington's Dis. 2012, 1:65-72.
136. Wu Y.H., Swaab D.F. The human pineal gland and melatonin in aging and Alzheimer's disease. J. Pineal Res. 2005, 38:145-152.
137. Wu Y.H., Swaab D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med. 2007, 8:623-636.
138. Wulff K., Porcheret K., Cussans E., Foster R.G. Sleep and circadian rhythm disturbances: multiple genes and multiple phenotypes. Curr. Opin. Genet. Dev. 2009, 19:237-246.
139. Wulff K., Gatti S., Wettstein J.G., Foster R.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 2010, 11:589-599.
140. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 2009, 5:311-322.
141. Zuccato C., Marullo M., Vitali B., Tarditi A., Mariotti C., Valenza M., Lahiri N., Wild E.J., Sassone J., Ciammola A., Bachoud-Lèvi A.C., Tabrizi S.J., Di Donato S., Cattaneo E. Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One 2011, 6(8):e22966.